Research
Hormonal
The FDA authorizes the use of injectable semaglutide for the treatment of obesity.
Practitioners can consider semaglutide as an approved treatment option for obesity in the U.S.
StrongSupportsmedium confidence
A Food and Drug Adminstration (FDA), que regula os medicamentos nos Estados Unidos, autoriza o uso de semaglutida injetável no tratamento da obesidade.
Why this rating
The claim is based on regulatory approval, which is a strong form of evidence.
Source
Uso de semaglutina no tratamento da obesidade / Use of semagglutin in the treatment of obesity
Ana Marcela Teodoro Timo et al. · Brazilian Journal of Health Review · 2022
DOI 10.34119/bjhrv5n3-207
otherCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →